|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Investments: | ||||||||||||||||||||
| Fixed maturity securities available-for-sale, at estimated fair value (net of allowance for credit loss of $224 and $249, respectively); and amortized cost: $347,781 and $337,201, respectively | ||||||||||||||||||||
| Equity securities, at estimated fair value | ||||||||||||||||||||
| Contractholder-directed equity securities and fair value option securities, at estimated fair value (includes $1,985 and $1,751, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Mortgage loans (net of allowance for credit loss of $1,358 and $1,193, respectively; includes $0 and $35, respectively, of mortgage loans held-for-sale) | ||||||||||||||||||||
| Policy loans | ||||||||||||||||||||
| Real estate and real estate joint ventures (includes $377 and $378, respectively, under the fair value option; $178 and $132, respectively, of real estate held-for-sale; $431 and $302, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Other limited partnership interests | ||||||||||||||||||||
| Short-term investments, principally at estimated fair value | ||||||||||||||||||||
| Other invested assets (includes $1,637 and $1,698, respectively, of leveraged and direct financing leases; $623 and $560, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash and cash equivalents, principally at estimated fair value (includes $357 and $96, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Premiums, reinsurance and other receivables | ||||||||||||||||||||
| Market risk benefits, at estimated fair value | ||||||||||||||||||||
| Deferred policy acquisition costs and value of business acquired | ||||||||||||||||||||
| Current income tax recoverable | ||||||||||||||||||||
| Deferred income tax asset | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Separate account assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Mezzanine Equity and Equity | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Future policy benefits | ||||||||||||||||||||
| Policyholder account balances | ||||||||||||||||||||
| Market risk benefits, at estimated fair value | ||||||||||||||||||||
| Other policy-related balances | ||||||||||||||||||||
| Policyholder dividends payable | ||||||||||||||||||||
| Policyholder dividend obligation | ||||||||||||||||||||
| Payables for collateral under securities loaned and other transactions | ||||||||||||||||||||
| Short-term debt (includes $114 and $117, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Long-term debt (includes $69 and $28, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Collateral financing arrangement | ||||||||||||||||||||
| Junior subordinated debt securities | ||||||||||||||||||||
| Current income tax payable | ||||||||||||||||||||
| Subordinated debt securities | ||||||||||||||||||||
| Notes issued by collateralized financing entities (includes all amounts: under the fair value option; and relating to variable interest entities) | ||||||||||||||||||||
| Deferred income tax liability | ||||||||||||||||||||
| Other liabilities (includes $374 and $167, respectively, relating to variable interest entities) | ||||||||||||||||||||
| Separate account liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| Equity | ||||||||||||||||||||
| MetLife, Inc.’s stockholders’ equity: | ||||||||||||||||||||
| Preferred stock, par value $0.01 per share; $2,905 aggregate liquidation preference | ||||||||||||||||||||
| Common stock, par value $0.01 per share; 3,000,000,000 shares authorized; 1,196,795,831 and 1,195,587,190 shares issued, respectively; 637,752,080 and 655,333,773 shares outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Treasury stock, at cost; 559,043,751 and 540,253,417 shares, respectively | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Total MetLife, Inc.’s stockholders’ equity | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities, mezzanine equity and equity | ||||||||||||||||||||
Loading...
